Tax Management India. Com
Law and Practice  :  Digital eBook
Research is most exciting & rewarding
  TMI - Tax Management India. Com
Follow us:
  Facebook   Twitter   Linkedin   Telegram

Home Case Index All Cases Central Excise Central Excise + SC Central Excise - 1995 (5) TMI SC This

  • Login
  • Cases Cited
  • Referred In
  • Summary

Forgot password       New User/ Regiser

⇒ Register to get Live Demo



 

1995 (5) TMI 98 - SC - Central Excise


  1. 2024 (12) TMI 1022 - SC
  2. 2023 (5) TMI 290 - SC
  3. 2023 (5) TMI 191 - SC
  4. 2015 (8) TMI 1012 - SC
  5. 2015 (8) TMI 250 - SC
  6. 2012 (12) TMI 149 - SC
  7. 2012 (3) TMI 40 - SC
  8. 2009 (4) TMI 6 - SC
  9. 2008 (9) TMI 4 - SC
  10. 2008 (5) TMI 46 - SC
  11. 2007 (10) TMI 3 - SC
  12. 2006 (3) TMI 141 - SC
  13. 2005 (4) TMI 57 - SC
  14. 2004 (12) TMI 92 - SC
  15. 2004 (10) TMI 93 - SC
  16. 2004 (5) TMI 68 - SC
  17. 2004 (2) TMI 68 - SC
  18. 2003 (10) TMI 48 - SC
  19. 2003 (4) TMI 102 - SC
  20. 2003 (4) TMI 103 - SC
  21. 2003 (4) TMI 98 - SC
  22. 2003 (1) TMI 103 - SC
  23. 2023 (12) TMI 757 - HC
  24. 2023 (8) TMI 179 - HC
  25. 2019 (7) TMI 1692 - HC
  26. 2019 (2) TMI 310 - HC
  27. 2018 (7) TMI 668 - HC
  28. 2018 (3) TMI 1487 - HC
  29. 2017 (3) TMI 535 - HC
  30. 2014 (12) TMI 1408 - HC
  31. 2014 (12) TMI 698 - HC
  32. 2014 (10) TMI 449 - HC
  33. 2015 (10) TMI 218 - HC
  34. 2012 (12) TMI 908 - HC
  35. 2014 (5) TMI 368 - HC
  36. 2011 (4) TMI 1033 - HC
  37. 2010 (10) TMI 233 - HC
  38. 2008 (9) TMI 845 - HC
  39. 2007 (7) TMI 634 - HC
  40. 2004 (1) TMI 94 - HC
  41. 2003 (11) TMI 107 - HC
  42. 2001 (10) TMI 1109 - HC
  43. 1995 (12) TMI 370 - HC
  44. 2024 (1) TMI 147 - AT
  45. 2023 (11) TMI 1087 - AT
  46. 2022 (12) TMI 1049 - AT
  47. 2021 (6) TMI 1026 - AT
  48. 2019 (12) TMI 522 - AT
  49. 2018 (6) TMI 376 - AT
  50. 2018 (2) TMI 1397 - AT
  51. 2018 (1) TMI 959 - AT
  52. 2017 (11) TMI 768 - AT
  53. 2017 (10) TMI 1182 - AT
  54. 2017 (5) TMI 235 - AT
  55. 2017 (3) TMI 1439 - AT
  56. 2016 (11) TMI 1274 - AT
  57. 2012 (11) TMI 682 - AT
  58. 2011 (6) TMI 626 - AT
  59. 2010 (4) TMI 325 - AT
  60. 2008 (8) TMI 179 - AT
  61. 2007 (5) TMI 31 - AT
  62. 2006 (10) TMI 51 - AT
  63. 2003 (1) TMI 408 - AT
  64. 2001 (12) TMI 250 - AT
  65. 2001 (10) TMI 146 - AT
  66. 2001 (5) TMI 671 - AT
  67. 1995 (9) TMI 198 - AT
  68. 2018 (8) TMI 772 - AAAR
  69. 2024 (9) TMI 1283 - AAR
  70. 2023 (7) TMI 810 - AAR
  71. 2021 (9) TMI 207 - AAR
  72. 2021 (3) TMI 140 - AAR
  73. 2020 (10) TMI 1292 - AAR
  74. 2018 (10) TMI 1871 - AAR
  75. 2009 (9) TMI 938 - AAR
Issues Involved:

1. Classification of the product 'Selsun' under the Central Excise Tariff.
2. Applicability of Chapter Notes and Rules of Interpretation.
3. Reliance on previous classifications and commercial parlance.
4. Consideration of the product as a drug or cosmetic.

Issue-wise Detailed Analysis:

1. Classification of the product 'Selsun' under the Central Excise Tariff:

The primary issue was whether 'Selsun' should be classified as a 'medicine' under sub-heading 3003.19 or as a 'cosmetic' under sub-heading 3305.90. The product 'Selsun' is manufactured under a Drug license and is used for treating skin diseases like dandruff and Tinea Versicolor. The Assistant Collector and Additional Collector of Central Excise initially classified it under sub-heading 3305.90, considering it a cosmetic due to its subsidiary curative value and the presence of other ingredients. However, the First Appellate Authority reversed this decision, classifying it under Chapter 30 as a drug, emphasizing that Selenium Sulphide is the only active ingredient used in therapeutic quantity.

2. Applicability of Chapter Notes and Rules of Interpretation:

The Tribunal's decision was based on the interpretation of Chapter Notes and the Rules of Interpretation. Chapter Note 2 to Chapter 33 states that products with subsidiary pharmaceutical constituents or curative value should be classified under Chapter 33. However, the Supreme Court found that for Note 2 to apply, the product must first be a cosmetic, suitable for use as a cosmetic, and labeled as such. The product 'Selsun' did not fulfill these criteria. The Court noted that the therapeutic quantity of Selenium Sulphide (2.5%) is the permitted amount, and anything in excess could be harmful, thus it cannot be considered subsidiary.

3. Reliance on previous classifications and commercial parlance:

The Court emphasized that the product had been classified as a patent and proprietary medicine under the old tariff item 14E, and there was no substantial reason to change this classification under the new tariff. The Central Board of Excise and Customs had previously classified 'Selsun' as a drug based on its therapeutic use, manufacturing under a Drug license, certification by the Food and Drugs Administration, and its inclusion in various pharmacopoeias. The Court also considered affidavits and letters from chemists, doctors, and customers, which supported the classification of 'Selsun' as a drug.

4. Consideration of the product as a drug or cosmetic:

The Court distinguished between cosmetics and drugs based on their intended use. Cosmetics are intended for cleansing, beautifying, or altering appearance, while drugs are used for treating or preventing diseases. 'Selsun' is intended for treating dandruff and other skin conditions, not for beautifying or altering appearance. The product's label and literature indicated its use as a medical treatment, with warnings and directions for use, further supporting its classification as a drug. The Court also rejected the argument that the product's pleasant odor and attractive packaging made it a cosmetic, noting that these factors do not change its medicinal character.

Conclusion:

The Supreme Court concluded that 'Selsun' should be classified under sub-heading 3003.19 as a medicine, not under sub-heading 3305.90 as a cosmetic. The appeals were allowed, and the product's classification as a drug was upheld. The Court found no justifiable reason to change the classification based on the new Central Excise Tariff Act, 1985, and emphasized that the product's true nature and intended use should determine its classification.

 

 

 

 

Quick Updates:Latest Updates